High court weighs generic drugmaker liability

By Lawrence Hurley WASHINGTON (Reuters) – Supreme Court justices weighed on Tuesday whether makers of generic drugs already approved by the Food and Drug Administration can be held liable under state law for claims of design defects. During a one-hour oral argument justices questioned whether federal law, in this case the requirement that generics have same design as the name-brand version, prevents plaintiffs from making such claims under state law. …